|Bid||43.40 x 1800|
|Ask||43.72 x 1200|
|Day's range||43.05 - 43.68|
|52-week range||32.99 - 46.29|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||307.80|
|Earnings date||26 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.87|
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.